Sangamo Therapeutics, Inc. and Pfizer Inc. today announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
from Dementia Big http://ift.tt/2mbFeiW via alcoholic dementia
http://ift.tt/2EmM1wN
No comments:
Post a Comment